Contemporary Practice Patterns of Flexible Ureteroscopy for Treating Renal Stones: Results of a Worldwide Survey

Casey A. Dauw, MD,1 Laika Simeon, BA,1 Abdulrahman F. Alruwaily, MBChB,1 Francesco Sanguedolce, MD,2 John M. Hollingsworth, MD, MS,1 William W. Roberts, MD,1 Gary J. Faerber, MD,1 J. Stuart Wolf, Jr., MD,1 and Khurshid R. Ghani, MBChB, MS1

Abstract

Introduction: Flexible ureteroscopy (fURS) is increasingly used in the treatment of renal stones. However, wide variations exist in technique, use, and indications. To better inform our knowledge about the contemporary state of fURS for treating renal stones, we conducted a survey of endourologists worldwide.

Methods: An anonymous online questionnaire assessing fURS treatment of renal stones, consisting of 36 items, was sent to members of the Endourology Society in October 2014. Responses were collected through the SurveyMonkey system over a 3-month period.

Results: Questionnaires were answered by 414 surgeons from 44 countries (response rate 20.7%). U.S. surgeons accounted for 34.4% of all respondents. fURS was routinely performed in 80.0% of institutions, with 40.0% of surgeons performing >100 cases/year. Respondents considered fURS to be first-line therapy for patients with renal stones <2 cm and lower pole calculi. A substantial minority (11.3%) preferred fURS as a primary treatment modality for renal stones >2 cm. Basket displacement for lower pole stones was routinely performed by 55.8%. Ureteral access sheaths (UAS) were preferred for every case by 58.3%. Respondents frequently utilized high-power lasers and dusting techniques. Criteria for determining stone-free rate were defined as zero fragments or residual fragment (RF) <1, <2, <3, and <4 mm by 30.9%, 8.9%, 31.5%, 15.8%, and 11.2% of respondents, respectively.

Conclusion: The overwhelming majority of endourologists surveyed consider fURS as a first-line treatment modality for renal stones, especially those <2 cm. Use of UAS, high-power holmium lasers, and dusting technique has become popular among practitioners. When defining stone free after fURS, the majority of endourologists used a zero fragment or RF <2 mm definition.

Introduction

TREATMENT OPTIONS FOR PATIENTS with renal stones mainly comprise one of three procedures: percutaneous nephrolithotomy (PCNL), shockwave lithotripsy (SWL), and flexible ureteroscopy (fURS). The ability to use the holmium laser to perform intracorporeal lithotripsy, as well as advances in endoscope technology and ancillary instrumentation, has seen fURS emerge as an increasingly popular method for managing patients with upper urinary-tract stones. In the United States, newly qualified urologists are increasingly using URS for the majority of stone removal procedures.1

Despite recent population-level evidence demonstrating increasing utilization of fURS,2-4 little information exists on contemporary practice patterns of fURS for the treatment of renal calculi.5 While guidelines recommend fURS for treating renal stones <1.5 cm,6 considerable differences exist among urologists in the technique, use, and indications of fURS. In particular, the variation in the use of disposable equipment, such as ureteral access sheaths (UAS) or nitinol retrieval devices, and the utilization of more powerful high-watt holmium laser systems in the modern era of fURS, have not been thoroughly evaluated. Recently, the European Association of Urology (EAU) conducted a survey on the use of fURS for the treatment of renal calculi in Europe.5 To study a broader collection of urologists throughout the world, we modified this questionnaire and surveyed members of the Endourology Society about multiple facets of renal calculus treatment using fURS. Our specific aim was to explore differences in the fURS technique and practice among endourologists.

1Department of Urology, University of Michigan Health System, Ann Arbor, Michigan.
2Department of Urology, North Bristol NHS Trust, Bristol, United Kingdom.
Methods

In October 2014, an anonymous online questionnaire characterizing fURS use in the management of renal stones was disseminated to all members of the Endourology Society through e-mail. The survey instrument contained 36 discrete questions divided into six domains to capture demographic information, level of surgeon experience, indications, surgical technique, postoperative stent management and tracking, and postsurgical follow-up. Questions were multiple choice with the option for free text responses. See Appendix for details on questions asked. Respondents were further subdivided based on region of residence for descriptive purposes such that those from North America, Europe, and other regions could be compared with respect to various responses.

The survey was conducted using the web-based SurveyMonkey system (Palo Alto, CA). Respondents were invited to participate through an introductory email from the Endourology Society membership office with a brief description of the survey and a hyperlink of the survey. A second reminder e-mail was sent a month later and the survey remained open for 3 months. The survey was deemed exempt from requiring review by the Institutional Review Board at the University of Michigan. To improve participation, a $200 award was offered to one respondent selected at random. The study was funded by the Endourology Division of the Department of Urology, University of Michigan.

Results

The survey was disseminated to ~2000 members of the Endourology Society; 414 (20.7%) responded. Those responding represented 44 countries with the largest percentage of respondents practicing in the United States (34.4%), United Kingdom (9.8%), and Canada (5.3%) (Table 1). More than 60% of respondents were between the ages of 40 and 59; 2% were <30 years, 23% were between 30 and 39 and 14% were older than 60 years. Approximately 60% of respondents had completed an endourology fellowship, while 80.5% indicated they were a subspecialist with an interest in urinary stone disease.

The case volume of fURS performed annually is depicted in Figure 1; nearly 40% of respondents performed fURS more than 100 times per year. fURS was performed routinely in the institution of 80% of respondents.

Table 1. Distribution of Urologists Responding to Survey on Flexible Ureteroscopy

<table>
<thead>
<tr>
<th>Country</th>
<th>Respondents (N)</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>3</td>
<td>0.8</td>
</tr>
<tr>
<td>Australia</td>
<td>4</td>
<td>1.1</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Belgium</td>
<td>3</td>
<td>0.8</td>
</tr>
<tr>
<td>Brazil</td>
<td>11</td>
<td>3.1</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>2</td>
<td>0.6</td>
</tr>
<tr>
<td>Canada</td>
<td>19</td>
<td>5.3</td>
</tr>
<tr>
<td>Chile</td>
<td>3</td>
<td>0.8</td>
</tr>
<tr>
<td>China</td>
<td>10</td>
<td>2.8</td>
</tr>
<tr>
<td>Colombia</td>
<td>8</td>
<td>2.2</td>
</tr>
<tr>
<td>Egypt</td>
<td>3</td>
<td>0.8</td>
</tr>
<tr>
<td>El Salvador</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>France</td>
<td>6</td>
<td>1.7</td>
</tr>
<tr>
<td>Germany</td>
<td>13</td>
<td>3.6</td>
</tr>
<tr>
<td>Greece</td>
<td>5</td>
<td>1.4</td>
</tr>
<tr>
<td>India</td>
<td>14</td>
<td>3.9</td>
</tr>
<tr>
<td>Indonesia</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Iran</td>
<td>4</td>
<td>1.1</td>
</tr>
<tr>
<td>Ireland</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Israel</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Italy</td>
<td>9</td>
<td>2.5</td>
</tr>
<tr>
<td>Japan</td>
<td>11</td>
<td>3.1</td>
</tr>
<tr>
<td>Lithuania</td>
<td>4</td>
<td>1.1</td>
</tr>
<tr>
<td>Mexico</td>
<td>8</td>
<td>2.2</td>
</tr>
<tr>
<td>Netherlands</td>
<td>6</td>
<td>1.7</td>
</tr>
<tr>
<td>Nigeria</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Norway</td>
<td>2</td>
<td>0.6</td>
</tr>
<tr>
<td>Pakistan</td>
<td>2</td>
<td>0.6</td>
</tr>
<tr>
<td>Philippines</td>
<td>3</td>
<td>0.8</td>
</tr>
<tr>
<td>Portugal</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Romania</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Russia</td>
<td>6</td>
<td>1.7</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>3</td>
<td>0.8</td>
</tr>
<tr>
<td>Singapore</td>
<td>4</td>
<td>1.1</td>
</tr>
<tr>
<td>South Africa</td>
<td>7</td>
<td>1.9</td>
</tr>
<tr>
<td>South Korea</td>
<td>2</td>
<td>0.6</td>
</tr>
<tr>
<td>Spain</td>
<td>7</td>
<td>1.9</td>
</tr>
<tr>
<td>Thailand</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>Turkey</td>
<td>8</td>
<td>2.2</td>
</tr>
<tr>
<td>United Arab Emirates</td>
<td>1</td>
<td>0.3</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>35</td>
<td>9.7</td>
</tr>
<tr>
<td>United States</td>
<td>123</td>
<td>34.3</td>
</tr>
<tr>
<td>Venezuela</td>
<td>1</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Indications and planning

With regard to indications and surgical planning, respondents overwhelmingly (96.4%) felt that fURS could be used as a first-line modality to treat renal stones. To this effect, there was a wide range of clinical situations in which respondents felt that fURS was an appropriate primary treatment, the most popular being stone in horsehoe kidney (72.1%) and stone in the lower pole (71%) (Fig. 2). Patients were considered for staged fURS (more than one URS planned in advance) when the renal stone size (cm) was 1–1.5 (9.7%), >1.5 (20.2%), >2.0 (27.0%), and >2.5 (16.3%).

Surgical technique

When examining techniques, there was variability in the way urologists approached the ureteral orifice before advancing the ureteroscope. Whereas some placed working and/or safety wires (38.0%), others first performed semirigid ureteroscopy (19.7%), retrograde pyelogram (14.6%), or placed a UAS (25.7%). Only 1.9% of respondents performed fURS without a wire.

In the event that the ureteroscope was unable to be advanced beyond the ureteral orifice, 27.6% of respondents stated they would dilate the orifice with ureteral dilators, 27.4% stated they would dilate with a semirigid ureteroscope, 25.5% stated they would place a ureteral stent and arrange for fURS at a later date, 18.2% would perform balloon dilation of the ureteral orifice, 1.1% would switch to another treatment modality, and 0.2% would perform a ureterotomy.

UAS/basket retrieval

Indications for use of UAS during fURS are provided in Figure 3, with 58.3% of respondents stating that they prefer to
use a UAS for every case. With regard to the strategy of whether to retrieve stone fragments or not, 26.7% of respondents actively retrieved all stone fragments, whereas 37.4% only retrieved large fragments—leaving those that were small enough to pass spontaneously (Fig. 4). When dealing with stones in the lower pole, most (55.8%) routinely used the basket displacement technique to move stones to a less dependent calix for fragmentation.

Holmium laser

Respondents uniformly utilized a holmium laser for stone fragmentation, and the vast majority worked in centers that owned their own laser (85.6%). High-power systems (≥100 W) were utilized by 41.1%, while lower power (20–30 W) systems were used by 44.2%. The majority of respondents (54.8%) preferred a 200-μm laser fiber size as their go to fiber. The dusting technique (i.e., low pulse energy and high frequency 0.2–0.5 J × 30–50 Hz) was used by 67% of the respondents.

Postprocedural aspects

Respondents indicated that in their practice, following completion of fURS, a ureteral stent was placed in all cases 63.9% of the time, whereas the remainder stated that a ureteral stent was only placed if warranted by intraoperative factors. Only 42.8% of respondents indicated that their practice maintained a stent registry to keep track of indwelling stents in patients (Fig. 5). Finally, respondents indicated that an abdominal radiograph, in combination with ultrasonography (40.8%), abdominal radiograph alone (32.8%), computed tomography (24.7%), or ultrasound alone (1.7%), was used to assess stone burden following fURS. The time point at which imaging was undertaken to assess the stone-free rate (SFR) varied (Fig. 6). Table 2 demonstrates the variation among urologists for determining what fragment size is important for defining the SFR.

Variation in technique by geographic location

After subdividing respondents by location of residence (North America, Europe, other), differences were noted with regard to selected questions as indicated in Table 3.

Discussion

The present survey-based study was conducted to better understand the worldwide variation in the fURS technique and clinical practice. In summary, the majority of urologists who responded were fellowship trained and many estimated a volume of more than 100 procedures performed annually. Most respondents felt fURS was applicable to a wide range of clinical scenarios, including varying stone size, stone location, and anatomic variations. Furthermore, respondents routinely used UAS and were familiar with high-watt holmium lasers for fURS, as well as using new techniques such as dusting for stone fragmentation.

One interesting observation highlighted by the survey results was that urologists find fURS to be an acceptable surgical technique for a wide range of indications. Recent EAU guidelines state that fURS is a reasonable option for treatment of renal stones <2 cm. In the present study, more than 10% of respondents indicated that fURS was considered an appropriate treatment for stones >2 cm, a size that traditionally
would be managed through PCNL. Moreover, despite a nonstatistical difference in SFRs reported in the prospective randomized controlled study comparing SWL with ureteroscopy for lower pole stones <1 cm, 71% of respondents felt fURS was the first-line therapy in this situation.7

Two recent studies have demonstrated that fURS is a reasonable approach for renal stones >2 cm. In a meta-analyses of urinary stones >2 cm managed by fURS, Aboumarzouk et al. found that for a mean stone size of 2.5 cm, SFRs were 93.7% with a major complication rate of 5.3%.8 A similar study by Breda and Angerri for stones >2.5 cm showed an overall SFR of 89.3% with a major complication rate of 8%.9 The average number of treatments required per patient was 1.6 in each study. These studies highlight that the combination of technologic advances and endourologic expertise may be broadening the application of fURS, a clinical impression reflected by our survey.

Another observation made from our study was the frequency with which surgeons utilized the UAS. More than half of respondents indicated in the survey that they used a UAS for every case, whereas an additional 25% used it in selected clinical scenarios. Advantages of the UAS include improving longevity of the flexible ureteroscope10 as well as decreasing intrarenal pressure during fURS.11 The UAS is often used to ease stone retrieval, as noted by 31.0% of respondents. Despite these benefits, outcomes such as SFR, arguably one of the most important indicators of effective fURS, have shown mixed results. L’esperance et al. evaluated 256 patients undergoing fURS for renal calculi stratifying outcomes based on whether a UAS was used or not. The SFR in the UAS group was 79%, significantly higher than the non-UAS group (67%).12 However, a more recent study did not find use of a UAS to be associated with improved SFRs with stone size being the only variable predictive of SFR on regression analysis.13 The paucity of evidence is reflected in the variation of use by respondents in our survey.

Our study provided some interesting findings with respect to practice patterns surrounding active stone retrieval vs fragmentation. Specifically, many respondents actively retrieved stone fragments and only a few indicated that they seek to fragment the stone into pieces they feel will pass spontaneously, without any need for extraction. Certainly, debate regarding the optimal fragmentation and retrieval technique has been ongoing.14 Currently, no Level 1 evidence is available that answers the following question: “should you perform active retrieval or is fragmentation only enough after fURS for renal stones?” More recently, newer laser lithotripsy techniques such as dusting utilizing high-watt holmium systems have been popularized.15 Dusting uses a high-frequency, low-pulse energy setting, such as 30–50 Hz × 0.2–0.5 J, which seeks to fragment stones to fine powder and small fragments, and thus reduce the need to retrieve fragments. We were surprised to find out that two-thirds of respondents indicated using this technique. So far, there are limited clinical data as to whether this method has significant advantages over existing techniques, and further studies are needed to confirm its utility.

Interestingly, more than 63% of respondents indicated that a ureteral stent was left in place following fURS. There have been numerous clinical trials conducted to investigate the utility of routine ureteral stenting following ureteroscopy. A recent systematic review and meta-analysis by Nabi et al. found that patients in whom a ureteral stent was placed reported higher rates of dysuria, urgency, and frequency without a statistically significant increased SFR, although this was limited by study heterogeneity.16 Given the uncertainty on this issue and lack of improvement in SFR reported in the meta-analysis, it is notable that so many respondents routinely stent their patients following fURS.

Our study has also provided some important information on determining the preferred method and criteria for determining the SFR after fURS. Approximately 75% used an abdominal radiograph, renal ultrasound, or a combination of the two as the imaging modality of choice for assessing residual stone burden. Most respondents use to perform this within 6 weeks following surgery. Certainly, use of ultrasound following URS is encouraged to rule out silent hydronephrosis, which can occur in up to 2%–5% of patients.17–19 Less agreed upon, however, is the definition of SFR following fURS. The term clinically insignificant residual fragment (RF) was introduced

![FIG. 5. Strategies for ureteral stent management and tracking.](image)

![FIG. 6. Time point after fURS when stone-free status is determined.](image)
for asymptomatic noninfectious RFs <4–5 mm following SWL, and many studies adopted this metric when reporting the success of stone treatment.20 However, recent computed tomography-based studies have shown that instead of RF ≤4 mm, sizes ≤2 or ≤3 mm might be more appropriate for determining the clinical significance of stone free and risk of retreatment after stone surgery.21,22 The lack of consensus in our field about imaging utilization and criteria23 is demonstrated in our study where nearly 30% felt stone free was defined as zero fragments on imaging, whereas the remainder felt RF <1–4 mm was appropriate.

Two prior surveys have investigated practice patterns surrounding upper tract urinary stone treatment use among urologists.24,25 Bandi et al. surveyed members of the North Central Section of the American Urological Association in 2006 and found that iURS was largely reserved for proximal and distal ureteral calculi. Subcentimeter renal stones were largely managed with SWL, whereas larger stones were managed with PCNL. This is in contrast to our study, where upward of 90% of urologists indicated iURS an appropriate first-line therapy for renal calculi of varying sizes and location. Our results are similar to a recent EAU survey conducted by Sanguedolce et al. wherein 95% of surveyed urologists preferred iURS as first-line therapy for renal calculi for a variety of clinical scenarios, and where also use of UAS was prevalent.26 Unlike our study, the EAU survey did not assess the use of holmium laser systems or practice patterns on postprocedure imaging and criteria for SFR.

The results of our study are useful in that they depict the demographics and practice patterns of an experienced group of specialty-trained urologists. However, certain limitations must be acknowledged. First, this study represents a highly specialized cohort of urologists, and thus, the findings may not be generalizable to general urologists without specialty training in endourology. In addition, our survey response rate of 21% is suboptimal and may influence the generalizability of our results. Furthermore, due to a general lack of rigorous level-one evidence regarding the benefit of several techniques described in the article (UAS use and dusting), observations from respondents serve more as descriptive findings rather than evidence of appropriate use. Moreover, the cost implications of technologic innovation with lack of proven benefit outside of observational studies must be considered carefully when treating patients with renal stones. Finally, there is always the possibility that due to reporting bias, opinions reflected in this survey do not necessarily mirror clinical practice. Nevertheless, our study response rate is similar to prior endourology surveys,24 and even higher than more recent ones to Endourology Society members.25 Finally, it is possible that some urologists may not be fully aware how best to utilize the holmium laser power settings, and further survey-based studies are needed to verify our findings.

**Conclusion**

The use of iURS for treating renal calculi has expanded such that it is considered first-line therapy by endourologists for varying stone sizes, stone locations, and anatomical variations. UAS, high-power holmium lasers, and dusting technique are now utilized on a regular basis. When defining stone-free status after iURS, the majority of urologists surveyed used a zero fragment or RF <2 mm definition. Although there is consensus regarding certain aspects of iURS technique and practice, several controversies still exist that merit further investigation.
Acknowledgments

We thank Greg Mowatt from the Department of Urology for helping with the IRB application, as well as Michele Paoli from the Endourology Society for assistance in disseminating the survey to its members.

Author Disclosure Statement

Khurshid Ghani is a consultant for Lumenis, Inc., and Boston Scientific.

References


Address correspondence to: Khurshid R. Ghani, MBChB, MS Department of Urology University of Michigan Health System 2800 Plymouth Road NCRC Building 16, 114W Ann Arbor, MI 48109 E-mail: kghani@med.umich.edu

Abbreviations Used

EAU = European Association of Urology
fURS = flexible ureteroscopy
KUB = kidney, ureter, and bladder radiograph
PCNL = percutaneous nephrolithotomy
RF = residual fragment
SFR = stone-free rate
SWL = shockwave lithotripsy
UAS = ureteral access sheath

(Appendix follows →)
Appendix—Survey Instrument

Question 1: What practice is your practice located in?

Question 2: How old are you?

Question 3: Do you have fellowship training in endourology/stones?

Question 4: Which of the following would you consider yourself?

- General urologist
- Urologist with specialty interest in stone disease
- Urologist with specialty interest in another area

Question 5: Approximately how often is flexible ureteroscopy used to treat renal stones at your center?

- Never
- Infrequently
- Sometimes
- Routinely

Question 6: Approximately how many flexible ureteroscopies to treat renal stones do you perform per year?

- 0
- <10
- 10–20
- 20–50
- 50–100
- >100

Question 7: If you do not perform flexible ureteroscopy for renal stones please select why not.

- Access to equipment
- Prefer different treatment modality
- Urolithiasis is not my specialty
- Other (explain)

Question 8: Do you think flexible ureteroscopy to treat renal stones can be considered a first-line procedure in specific cases?

- Yes
- No

Question 9: In which scenarios would you use flexible ureteroscopy to treat a stone?

- Lower pole stone
- Renal stone <1 cm
- Renal stone 1–2 cm
- Renal stone >2 cm
- Stone in caliceal diverticulum
- Stone in pelvic kidney
- Stone in horseshoe kidney
- Other

Question 10: When do you consider a patient for staged flexible ureteroscopy to treat renal calculi?

- Total renal stone burden 1–1.5 cm
- Total renal stone burden >1.5 cm
- Total renal stone burden >2 cm
- Total renal stone burden >2.5 cm
- I don’t perform staged procedures

Question 11: What steps do you typically perform before advancing a flexible ureteroscope?

- I place a working wire first
- I place a working and safety wire first
- I perform semirigid ureteroscopy first
- I place a ureteral access sheath first
- I perform a retrograde pyelogram first
- I perform flexible ureteroscopy without any wire
Question 12: If you are unable to advance a flexible scope beyond the ureteral orifice, which of the following procedures do you perform first?

- I perform passive dilation with ureteral dilator(s)
- I perform active dilation with a balloon dilator
- I perform a ureterotomy
- I place a ureteral stent and arrange for flexible ureteroscopy later
- I perform dilation with semirigid ureteroscopy
- I prefer to switch to another treatment option

Question 13: If you are able to advance flexible scope beyond the ureteral orifice but then unable to advance beyond the lower ureter, which of the following procedures do you perform first?

- I perform passive dilation with ureteral dilator(s)
- I perform active dilation with a balloon dilator
- I perform a ureterotomy
- I place a ureteral stent and arrange for flexible ureteroscopy later
- I perform dilation with semirigid ureteroscopy
- I prefer to switch to another treatment option

Question 14: How do you routinely advance the flexible ureteroscope into the kidney?

- Under fluoroscopic control
- Under direct vision
- Under fluoroscopic control and direct vision

Question 15: How do you consider the use of the ureteral access sheath during flexible ureteroscopy for treating renal stones? (Select all that apply)

- I prefer it for each case
- Only if large stone burden
- Only if ureter is prestented
- Only if aim is to proceed with active stone retrieval
- Never used
- Other

Question 16: Which size of ureteral access sheath (UAS) do you typically use (in nonstented ureter)?

- 9.5–11.5F
- 10–12F
- 11–13F
- 12–14F
- 13–15F
- 14–16F

Question 17: What is your main reason for using a UAS?

- To keep pressure in the collecting system low
- To perform retrieval of stone
- For better vision and irrigation
- It is easier to perform flexible ureteroscopy with this

Question 18: When inserting a UAS, what wire do you use for its placement?

- polytetrafluoroethylene (PTFE) wire
- Hydrophilic wire
- Hybrid wire
- Super-stiff wire

Question 19: When dealing with lower pole renal stones, what strategy do you follow?

- I prefer to displace the stone to a less dependent area with a nitinol basket and start fragmentation in a new area
- I prefer to start the fragmentation of the stone in situ in the lower pole
- Indifferent, I can retrieve the stone or not according to the situation
Question 20: Regarding fragmentation of a stone and whether to retrieve fragments or not, what is your typical strategy?

- I actively retrieve all fragments with a nitinol basket
- I retrieve only the bigger fragments with a nitinol basket and leave those that I think are small enough to pass spontaneously
- I don’t retrieve any fragments. I perform fragmentation of the stone until I think all the fragments are small enough to pass spontaneously
- I retrieve depending on the stone size and location
- I retrieve only in patients with prestenated ureters
- I retrieve only when stone is difficult to fragment into small bits or if anatomy is unsuitable for fragment passage

Question 21: Does your center/practice have access to a holmium laser for ureteroscopic lithotripsy?

Question 22: What power is your holmium laser?

- 20 W
- 30 W
- 50 W
- 60–80 W
- 100 W
- 120 W

Question 23: Is your laser ________________?

- Owned by center
- Leased but always on-site
- Leased and comes to center from outside as needed

Question 24: What is your standard “go to” laser fiber size when treating a renal stone?

- 150 fiber
- 200 fiber
- 270 fiber
- 365 fiber
- depends on location

Question 25: What is your standard setting on the holmium laser for stone fragmentation?

- 0.5–1.0 J × 5–10 Hz
- 0.5–1.0 J × 10–15 Hz
- 0.5–1.0 J × 15–20 Hz
- 1.0–1.5 J × 5–10 Hz
- 1.0–1.5 J × 10–15 Hz
- 1.0–1.5 J × 15–20 Hz
- 0.2–0.4 J × 30–50 Hz
- 0.5 × 20–50 Hz
- no standard setting; it varies with the situation
- other

Question 26: Do you use Dusting settings at all (i.e., Low Pulse Energy, High frequency 0.2–0.5 J × 30–50 Hz)?

Question 27: At the end of a routine flexible ureterorenoscopy to treat renal calculi

- I place a ureteral stent to be removed in the office at a later date
- I place an open-ended ureteral catheter, to be removed in 24 to 48 hours
- I don’t place a stent or ureteral catheter
- Whether or not I stent depends on intraoperative factors (time of surgery, residual fragments, ureteral injury, etc.)
- I place a stent to be removed by patient at home (stent on string)

Question 28: Do you ever use stent on string placement after flexible ureterorenoscopy to treat renal stones?

- Never
- Occasionally
- Routinely
Question 29: How many days is the maximum time you will instruct your patient to keep the stent (on a string)?

- 1 day
- 2 days
- 3 days
- 4 days
- 5 days
- >7 days
- It depends on the situation

Question 30: Do you or your center/practice maintain a ureteral stent registry to keep track and recall stents in patients?

Question 31: What method is used to keep track of stents?

- Paper-based system: managed by physician
- Paper-based system: managed by administrative assistant(s)
- Electronic stent registry integrated with electronic patient record
- Electronic stent registry that is not integrated with electronic patient record
- Other

Question 32: Have you ever failed to remove a ureteral stent in timely manner with consequences of patient morbidity?

Question 33: Have you ever managed a patient who had a forgotten ureteral stent?

Question 34: Which imaging modality do you use to determine stone free after flexible ureterorenoscopy?

- Kidney, ureter, and bladder radiograph (KUB) X-ray (XR) if stone radiopaque
- Ultrasound scan if stone is radiolucent
- KUB XR if radiopaque and ultrasound scan
- Ultrasound scan only regardless of stone lucency
- Non contrast CT of abdomen/pelvis
- Low-dose noncontrast CT of abdomen/pelvis

Question 35: At what time point do you assess stone-free rate after flexible ureterorenoscopy treatment for renal stones?

- 2 weeks
- 1 month
- 6 weeks
- 2 months
- 3 months
- 6 months

Question 36: What are the important stone size criteria for you when determining if a patient is stone-free?

- Patient must have zero fragments to be stone free
- <1 mm fragment is OK
- <2 mm fragment is OK
- <3 mm fragment is OK
- <4 mm fragment is OK
- <5 mm fragment is OK
This article has been cited by:

1. Natalia Hernandez Bustos, Alan Yaghoubian, Sarah Mozaifarpoor, Brian Eisner. History of the Development of Guidewires, Access Sheaths, Baskets, and Ureteral Stents 79–85. [Crossref]
2. Wesley Baas, Matthew Davis, Bradley F. Schwartz. Simulation in Surgery 439–488. [Crossref]
11. David Álvarez Villaraga, Juan David Iregui Parra, German Patiño Sandoval, Julián Chavarriaga Soto, Daniel Díaz Cardona. 2016. Ureterorenoscopia flexible: estado del arte y guía práctica de consejos y trucos. *Urología Colombiana* 25:3, 239–249. [Crossref]
15. Deok Hyun Han, Seung Hyun Jeon. 2016. Stone-breaking and retrieval strategy during retrograde intrarenal surgery. *Investigative and Clinical Urology* 57:4, 229. [Crossref]
16. Jiaqiao Zhang, Chouo Xu, Deng He, Yuchao Lu, Henglong Hu, Baolong Qin, Yufeng Wang, Qing Wang, Cong Li, Shaogang Wang, Jihong Liu. 2016. Flexible ureteroscopy for renal stone without preoperative ureteral stenting shows good prognosis. *Pier* 4, e2728. [Crossref]